More recently, there have been several exciting developments in the world of cancer immunotherapy, including checkpoint inhibitors (CTLA-4 and PD-1 antibodies), chimeric antigen receptor (CAR) T-cells, lymphocyte-promoting cytokines, agonistic antibodies against co-stimulatory receptors, as well as therapeutic cancer vaccines [58,59]. This evidence concerns the gene CTLA4 and cancer.